Investment
Features
FeesSafety
Academy
More
Pluang+

Inturai raises $1.275M via private placement to fund R&D and growth with shares and warrants.

Company Fundamentals
04 Aug 2026
PRNewsWire
View Source
Bullish
Inturai raises $1.275M via private placement to fund R&D and growth with shares and warrants.

Inturai Ventures Corp. announced a non-brokered private placement to raise up to $1,275,000 by issuing 8.5 million units at $0.15 each. Each unit includes one common share and one warrant exercisable at $0.25 within 24 months, allowing investors to benefit from future growth. The funds will support research and development, business expansion, and general working capital. The offering is subject to regulatory approval and includes potential finders' fees for introductions.

More News

Constellation Brands beats earnings and revenue estimates with strong beer and spirits sales.

Constellation Brands beats earnings and revenue estimates with strong beer and spirits sales.

Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...

Company Fundamentals
Bullish
2 hours ago
Tilray Brands to report Q1 2027 results with expected revenue growth and ongoing losses

Tilray Brands to report Q1 2027 results with expected revenue growth and ongoing losses

Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...

Company Fundamentals
Neutral
2 hours ago
Five stocks jump 21%-53% on news of acquisitions, blockchain, AI, and federal financing.

Five stocks jump 21%-53% on news of acquisitions, blockchain, AI, and federal financing.

On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...

Market News
Bullish
2 hours ago
Five stocks drop sharply on Oct 6, led by ArriVent BioPharma after lung cancer drug trial failure.

Five stocks drop sharply on Oct 6, led by ArriVent BioPharma after lung cancer drug trial failure.

On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...

Market News
Bearish
2 hours ago
Evercore raises Marvell's price target to $433 on strong AI and data center growth forecasts.

Evercore raises Marvell's price target to $433 on strong AI and data center growth forecasts.

Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App